Cardiovascular disease (CVD) is the leading cause of death in patients with diabetes mellitus. It represents a persistent risk that is inextricably linked to the diabetic disease state. For treating hyperglycaemia in patients with type 2 diabetes, there is a growing number of approved antidiabetic agents available both as monotherapy and combination therapy. Many of [...]
Reference: NICE clinical guideline 87 (update of NICE clinical guideline 66). The management of type-2 diabetes. May 2009. www.nice.org.uk/CG87
Reference: NICE clinical guideline 15. Type 1 diabetes: diagnosis and management of type 1 diabetes in adults. July 2004. www.nice.org.uk/CG15
Microvascular disease underlies the three most common and devastating complications of diabetes: retinopathy, nephropathy and neuropathy. Microvascular disease may also impair skin healing, so that even minor breaks in skin integrity can develop into deeper ulcers and easily become infected. The risk of developing these complications is proportional to the magnitude and duration of hyperglycaemia. [...]
Diabetes in pregnancy is associated with risks to the woman and to the developing foetus. Risks include foetal macrosomia, stillbirth, birth trauma (to mother and baby), transient neonatal morbidity, induction of labour or caesarean section, neonatal death, miscarriage, obesity and/or diabetes developing later in the baby’s life, and congenital malformation. Miscarriage, pre-eclampsia and preterm labour are [...]
Gestational diabetes is defined by the WHO as ‘carbohydrate intolerance resulting in hyperglycaemia of variable severity with onset or first recognition during pregnancy’. Risks of gestational diabetes include foetal macrosomia, birth trauma (to mother and baby), transient neonatal morbidity, induction of labour or caesarean section, neonatal hypoglycaemia, perinatal death, obesity and/or diabetes developing later in [...]
Depression frequently occurs comorbidly with type 1 and type 2 diabetes, although it may be unrecognised and untreated in many patients. In a meta-analysis, the odds of depression in diabetic patients were found to be twice that of non-diabetic patients and did not differ by sex, type of diabetes, subject source, or assessment method. In [...]
Dr Deirdre Blake, consultant endocrinologist and medical advisor to Novo Nordisk, presents a comparison of efficacy and safety in the treatment of type 2 patients, with inadequate control on metformin. The last several years have seen the launch of a number of incretin-based treatments for type 2 diabetes mellitus (T2DM). Incretins are hormones that stimulate [...]
Results from a randomised controlled trial presented at the 70th American Diabetes Association (ADA) Annual Scientific Sessions show that, in adults with type 2 diabetes with inadequate glycaemic control on metformin alone, the addition of saxagliptin 5mg to existing metformin therapy was non inferior in reducing glycosylated haemoglobin levels (HbA1c) compared to the addition of [...]
Loading ...
